K2 Biolabs
Houston, US · Founded 2021 · Delaware corporation · 15 employees on LinkedIn · 1 known investors
K2bio is a contract research organization offering in vivo study design, execution, and analysis in an AAALAC-accredited vivarium, along with in vitro research and pharmacology services for biotech and pharmaceutical partners. It also provides private lab spaces, benches, and scientific infrastructure for research teams in Houston's biotech hub.
Founders & leadership
DC
Daniel ClarkChief Financial Officer
KJ
Kieron JonesChief Executive Officer and Member of the Board of Directors
Board
KS
AD
Andrew DeSommaMember of the Board of Directors
GF
Gerard FleuryMember of the Board of Directors
CJ
Clifford J. StocksMember of the Board of Directors
AS
Andrew StrongMember of the Board of Directors
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.1M disclosed across 2 rounds · 2021–2023
▶$615.5KraisedAug 2023 · 7 investors · BiotechnologyRule 506(b)
▶$615.5KraisedAug 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew DeSommaDirector
- Gerard FleuryDirector
- Clifford J. StocksDirector
- Andrew StrongDirector
- Daniel ClarkExecutive Officer
- Kevin SlawinDirector
- Kieron JonesDirector, Executive Officer
- Offering amount
- $3M
- Amount sold
- $615.5K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5.5MraisedMar 2021 · 40 investors · BiotechnologyRule 506(b)
▶$5.5MraisedMar 2021 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KIERON JONESExecutive Officer, Director
- Andrew StrongDirector
- Andrew DeSommaDirector
- Kevin SlawinDirector
- Clifford StocksDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Minimum investment
- $25K
- Proceeds to insiders
- $270K
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
bio19 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
KALA BIO15 shared keywords
Krystalbio13 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
Coya Therapeutics13 shared keywords
Korro Bio12 shared keywordsKorro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
Companies competing with K2 Biolabs for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does K2 Biolabs do?
- K2bio is a contract research organization offering in vivo study design, execution, and analysis in an AAALAC-accredited vivarium, along with in vitro research and pharmacology services for biotech and pharmaceutical partners. It also provides private lab spaces, benches, and scientific infrastructure for research teams in Houston's biotech hub.
- Who are K2 Biolabs's investors?
- K2 Biolabs's investors include Rapha Capital Management, LLC.
- How much funding has K2 Biolabs raised?
- K2 Biolabs has disclosed $6.1M raised across 2 rounds.
- Where is K2 Biolabs headquartered?
- K2 Biolabs is headquartered in Houston, US.